316 related articles for article (PubMed ID: 31639439)
21. FANC pathway promotes UV-induced stalled replication forks recovery by acting both upstream and downstream Polη and Rev1.
Renaud E; Rosselli F
PLoS One; 2013; 8(1):e53693. PubMed ID: 23365640
[TBL] [Abstract][Full Text] [Related]
22. RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response.
Lyakhovich A; Shekhar MP
Oncogene; 2004 Apr; 23(17):3097-106. PubMed ID: 14981545
[TBL] [Abstract][Full Text] [Related]
23. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
24. Rad6/Rad18 Competes with DNA Polymerases η and δ for PCNA Encircling DNA.
Li M; Larsen L; Hedglin M
Biochemistry; 2020 Feb; 59(4):407-416. PubMed ID: 31887036
[TBL] [Abstract][Full Text] [Related]
25. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
26. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
[TBL] [Abstract][Full Text] [Related]
27. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
28. The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.
Bridge WL; Vandenberg CJ; Franklin RJ; Hiom K
Nat Genet; 2005 Sep; 37(9):953-7. PubMed ID: 16116421
[TBL] [Abstract][Full Text] [Related]
29. The RPA inhibitor HAMNO sensitizes Fanconi anemia pathway-deficient cells.
Jang SW; Kim JM
Cell Cycle; 2022 Jul; 21(14):1468-1478. PubMed ID: 35506981
[TBL] [Abstract][Full Text] [Related]
30. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin.
Zhang Z; Sun C; Zhang L; Chi X; Ji J; Gao X; Wang Y; Zhao Z; Liu L; Cao X; Yang Y; Mao W
Biomed Pharmacother; 2019 Jan; 109():1541-1546. PubMed ID: 30551406
[TBL] [Abstract][Full Text] [Related]
31. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability.
Bogliolo M; Lyakhovich A; Callén E; Castellà M; Cappelli E; Ramírez MJ; Creus A; Marcos R; Kalb R; Neveling K; Schindler D; Surrallés J
EMBO J; 2007 Mar; 26(5):1340-51. PubMed ID: 17304220
[TBL] [Abstract][Full Text] [Related]
32. Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways.
Su WP; Ho YC; Wu CK; Hsu SH; Shiu JL; Huang JC; Chang SB; Chiu WT; Hung JJ; Liu TL; Wu WS; Wu PY; Su WC; Chang JY; Liaw H
Sci Rep; 2017 Jun; 7(1):3879. PubMed ID: 28634400
[TBL] [Abstract][Full Text] [Related]
33. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
[TBL] [Abstract][Full Text] [Related]
34. BRCA1-independent ubiquitination of FANCD2.
Vandenberg CJ; Gergely F; Ong CY; Pace P; Mallery DL; Hiom K; Patel KJ
Mol Cell; 2003 Jul; 12(1):247-54. PubMed ID: 12887909
[TBL] [Abstract][Full Text] [Related]
35. A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage.
Chen X; Bosques L; Sung P; Kupfer GM
Oncogene; 2016 Jan; 35(1):22-34. PubMed ID: 25893307
[TBL] [Abstract][Full Text] [Related]
36. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
[TBL] [Abstract][Full Text] [Related]
37. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Domagala P; Hybiak J; Cybulski C; Lubinski J
Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
[TBL] [Abstract][Full Text] [Related]
38. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
39. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
Zheng H; Shao F; Martin S; Xu X; Deng CX
Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
[TBL] [Abstract][Full Text] [Related]
40. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
